*Interroll Holding AG reported a 3.8% increase in sales in 2022 to 664.4 million Swiss francs ($721.70 million).
* Novartis AG unit Sandoz received a positive opinion from the European Medicines Agency's CHMP committee to
market a high concentration formulation of its biosimilar Hyrimoz® (adalimumab) for rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis and uveitis.
* Polypeptide Group said Raymond de Vre resigned, but will "remain available for a smooth transition" to his successor ANALYSTS' VIEWS HOLCIM : HSBC RAISES TARGET PRICE TO CHF 62 FROM CHF 60 SIKA : HSBC CUTS TARGET PRICE TO CHF 330 FROM CHF 420
ROCHE HOLDING AG : BERENBERG CUTS TARGET PRICE TO CHF 350 FROM CHF 380 GIVAUDAN : BARCLAYS CUTS TARGET PRICE TO CHF 2850 FROM CHF 3000 SGS SA : MORGAN STANLEY CUTS TO UNDERWEIGHT FROM EQUAL WEIGHT; CUTS TARGET PRICE TO CHF 2100 FROM CHF 2220 ECONOMY Swiss KOF indicator due at 0800 GMT
SNB data on Swiss sight deposits due at 0900 GMT ($1 = 0.9206 Swiss francs) (Reporting by Zurich newsroom and Berlin Speed Desk)
Daily Swiss stock market report in German All SMI constituent stocks DJ STOXX index Top 10 STOXX sectors Top 10 EUROSTOXX sectors Swiss mid-cap index Swiss all-share index Swiss market digest Sector overview All Swiss news Swiss research news All equity news SPEED GUIDES: ))